Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Indonesia to ink Pfizer, AstraZeneca vaccine deals as awaits Sinovac clearance

Tue, 29th Dec 2020 11:38

(Recasts, adds vox pops on vaccine hesitancy)

By Stanley Widianto and Yuddy Cahya Budiman

JAKARTA, Dec 29 (Reuters) - Indonesia is poised to secure
coronavirus vaccines from Pfizer and AstraZeneca, the health
minister said on Tuesday, as it awaits authorisation to begin
its inoculation programme with a third drug, by China's Sinovac.

Budi Gunadi Sadikin said a 50-million-dose deal with
AstraZeneca would be finalised before the end of the
year, and one of the same size with Pfizer in the first
week of January.

The first shots for both those drugs, which have gained
regulatory approval in many western countries, are not scheduled
to arrive for months, the minister told his first news
conference.

So Indonesia plans to start vaccinations with the Sinovac
treatment, of which it secured 1.2 million doses this
month and expects 1.8 million more in January, once it gains
emergency use clearance.

Interim results from its phase III trial are expected to be
delivered to Indonesia's Food and Drug Agency next month.

Budi said the country's 1.3 million front-line health
workers would get priority in the first wave of vaccinations
between January and April. "They are the most important group of
people in our battle against the pandemic," he told a news
conference.

The world's fourth most populous country has had over
727,000 confirmed COVID cases and 21,700 deaths, among Asia's
highest tallies.

Public servants will be next in line for shots, with those
in infection "red-zones" aged between 18 and 59 prioritised in a
second round of vaccinations.

Indonesia is focusing its programme on that age range rather
than the elderly in an effort to safeguard the working
population.

Bambang Heriyanto, corporate secretary of state-owned
drugmaker Bio Farma, said that strategy would allow Indonesia to
reach herd immunity.

Including Tuesday's announcement, Indonesia has secured 329
million vaccine doses, including about 125 million from Sinovac,
50 million from Novavax and 54 million from global vaccine
programme COVAX.

The AstraZeneca vaccines are expected to arrive in the
second quarter of 2021 and Pfizer's in the third quarter,
according to a slide presentation by Budi.

The companies were not immediately available for comment.

IS IT SAFE? IS IT HALAL?

The vaccine deals met with mixed reactions on the streets of
the capital Jakarta on Tuesday.

"There's lots of diseases with no cure, but there's already
(a) cure for COVID," said 25-year-old radio announcer Cindy
Lauw, "I'm just wary."

Suhaimi, a 55-year-old retiree, said he would await trial
results, and news about whether the vaccine was permitted under
Islam.

A December survey by Indonesian pollster Saiful Mujani
Research and Consulting showed 37% of 1,202 respondents were
willing to be vaccinated, while 40% would consider it and 17%
would refuse.

While acknowledging the essential role of vaccinations,
epidemiologist Pandu Riono warned against over-reliance on them.

"Vaccines are the second step in prevention, the first is
behaviour and surveillance, testing, contact tracing and
isolation," he said.
(Additional reporting by Angie Teo;
Writing by Kate Lamb;
Editing by Martin Petty, Robert Birsel and John Stonestreet)

More News
Today 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.